Search Resources (English): Drug industry

Results 1 - 10 of 71


A different prescription: considerations for women's health groups contemplating funding from the pharmaceutical industry

Discusses diverse perspectives on the issue of women's health groups accepting money from the pharmaceutical industry.

 (See Details)
Published: 1999
Transparency in drug regulation: mirage or oasis?

Criticizes the Therapeutic Products Directorate (TPD), the arm of Health Canada in charge of testing and approving new drugs, particularly its dependence on funding from the pharmaceutical industry. Finds that these close ties with the pharmaceutical firms has led to the concealment of scientific or technical information about the safety and efficacy of new drugs.

 (See Details)
Published: 2004
Patents, pills and public health: can TRIPS deliver?

Aims to provide the media, policy-makers, non-governmental organizations and other concerned groups with an introduction to the issues surrounding the international agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and public health.

 (See Details)
Published: 2002
Tales from the other drug wars

Explores how the pharmaceutical industry encourages certain types of research that do not cure but require patients to remain on medication long term.

 (See Details)
Published: 2000
The marketization of depression: the prescribing of SSRI antidepressants to women

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

 (See Details)
Published: 2005
"This may sting a bit": cutting CME's ties to pharma
Argues against pharmaceutical industry funding of continuing medical education (CME).
Published: 2006
Drugs in the news: how well do Canadian newspapers report the good, the bad and the ugly of new prescription drugs?

Examines whether Canadians can rely on daily newspapers to provide them with accuracte, credible information about new drugs. Demonstrates that newspaper articles more often emphasized the benefits of new drugs, paying less attention to possible harms, regardless of the length of the article and often failed to distinguish between real clinical benefits of a drug and merely changes in some measurement that is only a risk factor for disease. (See Details)

Published: 2003
The global drug-pushers: globalization is not good for women's health. Here's why

Debates that women, in particular, are vulnerable to the changes being wrought in the name of globalization. Discusses the negative impact that the pharmaceutical industry has had on women's health.

 (See Details)
Published: 2002
Medical products and the Internet: WHO's guide to safe surfing

Provides a guide to obtaining reliable, independent and comparable information on medical products on the World Wide Web. Developed in consultation with drug regulatory authorities, drug information experts, consumer organizations and the pharmaceutical industry.

 (See Details)
Published: 2001
Statement of the International Working Group on Transparency and Accountability in Drug Regulation

Discusses the origins of confidentiality in drug regulation, the scope of regulations, the development and consequence of excessive secrecy in drug regulation, the benefits of openness of drug information, and the need for transparency at the international level.

 (See Details)
Published: 1997